Particle engineering for precise uniform drug particle production
Liquidia received the foundation’s support for the application of Liquidia PRINT® technology to vaccine development for infectious diseases.
-
Domain
-
Investment typeDirect equity
-
StatusExit
-
Initial investmentSeries C
-
Partnered in2011
-
Investment leadDavid Rossow
-
HeadquartersUSA
-
Program strategyPneumonia
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.